Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAvMed Small Group ACA 5-Tier Formulary Update | Op…
    Ask Trek AI about this page
    CurrentAvMedPolicy N/A

    Small Group ACA 5-Tier Prescription Drug Formulary (Non-Standard Plan)

    Customize your policy alerts

    Sign up for all AvMed policy alerts

    Know when AvMed releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines AvMed's non-standard 5-tier prescription drug formulary for small group ACA employer plans, including formulary structure, coverage processes (prior authorization, step therapy, quantity limits), exclusions, and member pharmacy requirements; affects members and prescribers using this plan.

    Policy Summary
    PayerAvMed
    PolicySmall Group ACA 5-Tier Prescription Drug Formulary (Non-Standard Plan)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionProviders must submit a completed drug authorization request form with supporting clinical documentation to obtain prior authorization for certain drugs (fax 1305-671-0200); decisions issued within 24 hours for urgent requests and 1–3 business days for standard requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5-tierformulary tier structure described
    24h / 1-3dprior authorization timelines
    30-dayspecialty supply limit
    90-day

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    retail/mail supply option
    QL, PA, SP, STutilization management types

    Formulary Coverage & Drug-Level Controls

    Coverage rules and limitations

    Coverage is subject to member-specific benefit parameters and the plan's utilization management rules. Coverage decisions and member responsibilities are summarized below.

    AvMed may modify coverage criteria and the formulary at any time; the formulary is reference only and does not guarantee benefits (see Member Engagement for benefit questions).

    Source: formulary preface and coverage notice.

    Members must follow plan-specific benefit parameters; coverage may vary by member and group plan.

    Contact Member Engagement; formulary does not reflect all member-specific benefits.

    Members should obtain medications from in-network pharmacies as required by their plan and follow retail/mail supply rules below.

    Retail/mail supply options described in member benefits.

    Supply limits: Specialty drugs are limited to a 30-day supply and are dispensed via Plan Specialty Pharmacy unless otherwise noted; retail prescriptions may be dispensed up to 90 days where allowed; mail-service provides 31–90 day supplies per benefit.

    Includes specialty 30-day limit and retail/mail options.

    Mandated generic substitution is encouraged; if a brand product is requested when an FDA-equivalent generic exists, the member may pay the Non-Preferred Brand copay plus a Brand Additional Charge.

    Generic substitution policy described.

    Common exclusions: OTC products (unless specified), experimental/unapproved/foreign meds, fertility drugs (unless specified), sexual dysfunction treatments (unless specified), vitamins/minerals, nutritional supplements/medical foods, cosmetics, appetite suppressants (unless specified), and most compounded prescriptions (except pediatric).

    List of commonly excluded items.

    Drugs covered under the medical benefit (e.g., physician-administered immunizations, dressings, medical supplies, chemotherapy administered in medical setting) are not covered under the pharmacy formulary and follow the Group Medical and Hospital Service Contract.

    Medical-benefit vs pharmacy-benefit distinction.

    Non-formulary and Clinically Equivalent Drug (CED) requests require clinical documentation (medical records/claims) demonstrating medical necessity, contraindication to formulary alternatives, or therapeutic failure; prior authorization may be required for exceptions.

    Requirements for non-formulary/CED requests.

    Quantity limit exceptions and other utilization management exceptions require the prescriber to submit a statement of medical necessity and request prior authorization as applicable.

    Quantity limit exception process.

    Providers must obtain prior authorization where indicated by the formulary by submitting a completed drug authorization request form and supporting clinical documentation to AvMed (fax number provided in full policy). Urgent requests: decision within 24 hours; standard requests: decision within 1–3 business days.

    Prior authorization process and timelines.

    Sample drug coverage entries

    Selected example drug-level coverage entries from the formulary (partial list). Each entry shows drug name, assigned tier, and any applicable utilization controls or quantity limits.

    fluconazole oral tablet (100 mg, 200 mg): Tier 2; QL (4 per 1 day).
    fluconazole oral tablet (150 mg): Tier 2; QL (4 per 30 days).
    flucytosine: Tier 3; PA required.
    itraconazole oral capsule: Tier 3; QL (4 per 1 day).
    NOXAFIL oral suspension (delayed release): Tier 4; PA required; QL (1 per 1 day).
    posaconazole oral suspension: Tier 3; PA required; QL (20 per 1 day).

    COVERAGE CRITERIA

    Formulary coverage is expressed per drug by tier and any specific requirements/limits such as PA, SP, LA, ST, or QL.

    Drugs are assigned to tiers 1–5 (and tier 9 for certain preventive/vaccine items); tier assignment affects cost-sharing and preferred status.

    Tier definitions referenced in formulary legend.

    Utilization controls

    • PA — Prior Authorization required (indicated as 'PA').
    • SP — Specialty Pharmacy requirement (indicated as 'SP').
    • LA — Limited Access or life-cycle/age limits (indicated as 'LA').
    • ST — Step Therapy required prior to coverage (indicated as 'ST').

    Coverage stance for listed drugs

    Coverage stance and utilization control patterns observed in the formulary (representative examples).

    Many listings, especially Tier 5 specialty agents, include combinations of PA; SP; and QL, with occasional LA (limited access) or age-based PA.
    Examples: XALKORI (Tier 5) — PA; SP; QL (4 per 1 day). EPCLUSA (Tier 5) — PA; SP; QL (1 per 1 day). IMBRUVICA formulations (Tier 5) — PA; SP; QL (varies by strength).
    Quantity limits for oncology and specialty products frequently reference per-day or per-28/30/365-day limits to align with dosing and packaging constraints.

    Sample per-drug coverage entries

    More per-drug examples demonstrating tier placement and utilization controls from neurology/anticonvulsant and other therapeutic areas.

    XALKORI oral capsule: Tier 5; Requirements = PA; SP; QL (4 per 1 day).
    EPIDIOLEX: Tier 5; Requirements = PA; SP; LA.
    LEVETIRACETAM oral tablet: Tier 2; no specific requirements listed in this excerpt.
    NAYZILAM: Tier 4; Requirements = PA; QL (10 per 30 days).
    INBRIJA inhalation capsule: Tier 5; Requirements = PA; SP; QL (10 per 1 day).

    Formulary tiers and per-drug requirements (partial)

    Formulary tier assignments and per-drug requirements illustrate common enforcement of PA, QL, ST and SP flags.

    Tier assignments span preferred generics (Tier 1) through specialty (Tier 5); specific entries list the drug tier followed by Requirements / Limits column flags.
    Prior authorization (PA) appears frequently and is often coupled with age-based restrictions for certain injectable/long-acting products (e.g., PA for age <=17).
    Step therapy (ST) is applied for selected agents and is indicated where trial of other agents is required before coverage of the listed product.
    Quantity limits (QL) accompany many entries and are specified as counts over defined time periods (per day, per 28 days, per 365 days).

    Coverage criteria summary for listed drugs

    Summary observations on coverage criteria patterns across the formulary extract.

    Drugs assigned to higher tiers (4–5) more commonly require PA and SP and have QL constraints; lower tiers (1–3) generally have fewer utilization controls but may still have QLs or ACA flags.
    Pediatric or age-based PA is used for many injectables/long-acting formulations (multiple entries show PA for Age <= 17).
    Some products combine multiple controls (e.g., PA; SP; LA) reflecting limited access or special distribution requirements for safety or cost reasons.
    Operationally, the Requirements / Limits column should be referenced for each drug line to determine whether prior authorization, specialty pharmacy, step therapy, limited access, quantity limits, or ACA/OTC flags apply.

    Coverage criteria by drug

    Drug-specific coverage criteria examples illustrating tier, utilization controls, age limits, and quantity limits.

    TRINTELLIX: Drug Tier = 4; Requirements = PA; QL (1 per 1 day).
    trifluoperazine: Drug Tier = 3; Requirements = PA for Age <= 17; QL (4 per 1 day).
    UZEDY subcutaneous suspensions (various strengths): Drug Tier = 3; Requirements = PA for Age <= 17; QL (strength-specific per 28 days).
    XYWAV: Drug Tier = 5; Requirements = PA; SP; LA; QL (18 per 1 day).
    ZURZUVAE oral capsule 20 mg/25 mg: Drug Tier = 5; Requirements = PA; SP; QL (28 per 14 days).
    ZYPREXA RELPREVV intramuscular suspension 210 mg/300 mg: Drug Tier = 3; Requirements = PA for Age <= 17; QL (2 per 28 days).

    Selected coverage criteria examples

    Selected coverage entries showing tier, utilization controls, and examples of quantity limits for biologic and other specialty products.

    HYMPAVZI PEN: Tier 5; Requirements = PA; SP; QL (4 per 28 days).
    MULPLETA: Tier 5; Requirements = PA; SP; QL (7 per 365 days).
    QFITLIA PEN: Tier 5; Requirements = PA; SP; QL (0.5 per 28 days).
    atorvastatin oral tablet (10 mg, 20 mg): Tier 1; Requirements = ACA (preventive coverage indication where applicable).
    REPATHA SURECLICK: Tier 3; Requirements = PA; QL (3 per 28 days).
    DUPIXENT pen 300 mg/2 mL: Tier 5; Requirements = PA; SP; QL (4 per 28 days).

    Selected coverage entries (examples)

    Representative product-level coverage examples across therapeutic areas and associated utilization controls.

    Lidocaine topical adhesive patch 5%: Tier 3; QL (3 per 1 day).
    LULICONAZOLE: Tier 4; Requirements = PA.
    SANTYL: Tier 4; Requirements = QL (2 per 720 days).
    IMCIVREE: Tier 5; Requirements = PA; SP; QL (9 per 30 days).
    Entries across classes are covered with criteria — consult the specific drug line for applicable PA, SP, ST, LA, and QL requirements.

    Formulary coverage with utilization controls

    Formulary entries for devices, insulin/supplies, and metabolic agents with utilization controls and typical quantity limits.

    CGM devices and sensors (Dexcom G6/G7): typically Tier 4; Requirements = PA; CGM designation; QL often expressed as 1 receiver per 365 days and sensors per 28–30 days depending on model.
    Insulins: Many insulins are Tier 3 with a common limit of 100 units per 30 days for standard supplies; some insulin systems/pumps and associated supplies have product-specific QLs (e.g., Omnipod pods QL 10 per 30 days; intro kits QL 1 per 720 days).
    Non-insulin antidiabetics: examples include MOUNJARO (Tier 3) — PA; QL (2 per 28 days); OZEMPIC oral tablet (Tier 3) — PA; QL (30 per 365 days).
    Operators: For device or supply claims, reference the device/CGM line for PA and QL specifics as these differ by model and dispenser rules.

    Examples of coverage requirements for biotech agents

    Biotechnology and biologic agent examples showing specialty designations and quantity limits.

    NEUPOGEN injection solutions and syringes: Tier 5; Requirements = PA; SP; QL (varies by strength, e.g., 3 per 1 day for some strengths).
    Many biotech agents (e.g., Neulasta, Nivestym, Procrit) are Tier 5 and require PA and SP; QLs are specified per product and strength.
    Vaccine examples: numerous vaccines are Tier 9 with 'ACA' designation for preventive coverage; some vaccines have age-based PA requirements (e.g., ABRYSVO PA for age <= 49).

    Vaccine coverage flags

    Vaccine and preventive immunization flags used in the formulary.

    Vaccines and routine immunizations are often listed under Tier 9 or indicated with 'ACA' to denote Affordable Care Act preventive coverage where applicable.
    Some vaccine entries include age-based prior authorization (e.g., ABRYSVO entry shows PA for age <= 49).

    Non-biologic therapy coverage examples

    Examples of non-biologic therapy coverage and typical tiering for common agents.

    Allopurinol oral tablet 100 mg, 300 mg: Tier 2; no specific utilization controls listed.
    Alendronate oral tablet 10 mg: Tier 1; QL (1 per 1 day).
    Risedronate oral tablet 150 mg: Tier 3; QL (1 per 28 days).
    Ophthalmic agents: many ophthalmic antibiotics and allergy eye products are Tier 2–4 with occasional QLs; specialty ophthalmic therapies (CYSTADROPS, OXERVATE) are Tier 5 with PA; SP; QL constraints.

    Per-drug coverage entries (select examples)

    Additional per-drug examples illustrating specialty biologic controls and OB/GYN product requirements.

    Many specialty biologics (rheumatology, dermatology) are Tier 5 and list PA; SP; and QL (e.g., ACTEMRA — PA; SP; QL 3.6 per 28 days; ADALIMUMAB biosimilars — PA; SP; QL 2 per 28 days).
    OB/GYN drug examples: MYFEMBREE — Requirements = PA; QL (1 per 1 day); ORIAHNN — Requirements = PA; QL (2 per 1 day).
    Step therapy examples: certain products (e.g., RASUVO) are designated ST indicating prior trial requirements before coverage of the listed product.

    Coverage criteria by tier and drug/group

    Tier-based coverage patterns and group-level examples for contraceptives, ophthalmics, respiratory, and common OTC categories.

    Many contraceptives and estrogen/progestin products are Tier 2 and flagged 'ACA' for preventive coverage where applicable. Examples include tri-lo-marzia, tri-sprintec, and others listed as ACA.
    Ophthalmic antibiotics and allergy eye products span Tiers 2–4; some have QLs while others have no utilization limits in the extract.
    Specialty ophthalmic therapies (e.g., CYSTADROPS, OXERVATE): Tier 5 and require PA; SP; and QL with specific numeric limits.
    Respiratory and pulmonary specialty drugs cover Tiers 3–5 and frequently include PA; SP; LA and QL depending on agent.
    Common OTC and lower-tier allergy/antihistamine agents (e.g., ketotifen, budesonide nasal) appear as Tier 2 or OTC with no limits or ACA designation as specified.

    Codes, Tier Mapping & Quantity Definitions

    N/A in this sectionmixed
    Formulary tier codes and meaningsmixed
    1Preferred Generic
    2Generic
    3Preferred Brand
    4Non-Preferred Brand
    5Specialty Drugs
    9Zero Cost Share Preventive Drugs
    NDC/Coding not providedNDC
    No procedure or diagnosis codes provided in this excerpt; entries are drug names with tier and requirements.
    Codes not providedmixed
    No explicit billing or NDC/CPT/HCPCS codes provided in this extract.
    Formulary utilization control codesmixed
    PAPrior authorization required
    SPSpecialty pharmacy requirement
    LALimited access / limited availability
    QLQuantity limit specified
    STStep therapy required
    Formulary requirement codesmixed
    PAPrior authorization required
    QLQuantity limit (units per time period)
    STStep therapy
    SPSpecialty
    LALimited access
    Drug identifiersNDC
    NDC codes are not provided in this extract; drug names, strengths, tiers and requirement abbreviations are listed.
    Formulary entries (drugs without procedure codes)mixed
    No explicit coding (CPT/HCPCS/ICD-10/NDC) present in these chunks; entries are drug names, tiers, and requirement flags.
    Formulary tiersmixed
    Tier 1-5Formulary tier assignments for drugs (examples: Drug Tier = 1,2,3,4,5).
    Formulary tier assignmentsmixed
    Drug tier designations (numeric tiers 2–5 and 9) are used to indicate formulary placement for each listed product.
    Device/NDC-like listings (no NDCs provided)mixed
    DEXCOM G6/G7 devices and sensors listed with tiers and QL; no NDCs provided in this extract.
    Formulary tier assignmentsmixed
    Drug-tier numeric mapping is presented (individual products assigned tiers 1–5,9); no standardized billing codes shown.
    formulary tier and requirement annotationsmixed
    Drug names with assigned formulary tiers and requirements (e.g., esomeprazole magnesium — tier 2, QL; lansoprazole — tier 2, QL).
    Formulary tier and requirement flagsmixed
    Formulary entries use tier numbers and requirement flags (PA, SP, QL, ST, ACA, OTC) rather than standardized billing codes in this excerpt.
    Formulary tier mappingmixed
    Drug tier assignments (Tier 1-5 and 9) as provided in formulary list; no CPT/HCPCS/ICD codes present in this section.
    Retail/mail supply limitmixed
    Retail supplyUp to 90-day supply (retail) as allowed by plan
    Mail-service supply31 to 90-day supply via mail-service per prescription benefits
    Specialty supplySpecialty drugs limited to a 30-day supply via Plan Specialty Pharmacy

    Authorization, Step Therapy & Prescriber Requirements

    Prior Authorization

    Prior authorization: submit completed request form and clinical documentation

    The ordering prescriber must submit a completed drug authorization request form and supporting clinical documentation to AvMed by fax (1305-671-0200). Information that may be required includes lab values, prescription history, a statement of medical necessity, and any other pertinent clinical information. Urgent prior authorization decisions will be made within 24 hours; standard determinations are made within 1–3 business days.

    • Submit completed drug authorization request form (available at https://www.avmed.org/prescriptions/ or https://www.avmed.org/forms/provider).
    • Include supporting clinical documentation: lab values, prescription history, statement of medical necessity, and other pertinent information.
    • Fax submissions to 1305-671-0200.
    • Expect decisions within 24 hours for urgent requests and 1–3 business days for standard requests.
    Documentation Required

    Key Terms & Abbreviations

    Brand Medication definition
    DefinitionBrand Medication — a prescription medication sold under a brand/trademark by a manufacturer or identified as a Brand by AvMed's PBM.
    Additional noteWhen a brand is chosen over an available generic, a Brand Additional Charge (difference between brand and generic cost) may apply in addition to the copayment.
    Formulary contextBrand medications are listed on the formulary and may receive tier placement that affects copay and coverage.
    Generic Medication definition
    DefinitionGeneric Medication — a prescription medication with the same active ingredient as a brand product, FDA-approved and considered as effective and safe as the brand-name product.
    Cost implicationGenerics are generally lower cost than brand products and are preferred where available.
    Policy Summary
    PayerAvMed
    PolicySmall Group ACA 5-Tier Prescription Drug Formulary (Non-Standard Plan)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionProviders must submit a completed drug authorization request form with supporting clinical documentation to obtain prior authorization for certain drugs (fax 1305-671-0200); decisions issued within 24 hours for urgent requests and 1–3 business days for standard requests.
    SourceLink
    On This Page
    Formulary Coverage & Drug-Level ControlsCodes, Tier Mapping & Quantity DefinitionsAuthorization, Step Therapy & Prescriber RequirementsKey Terms & Abbreviations
    VIVJOA: Tier 4; PA required; QL (18 per 84 days).
    abacavir / abacavir-lamivudine combinations: Tier 3; SP (specialty) designation for many formulations.
    APTIVUS (ap-tivus): Tier 5; SP (specialty).
    PAXLOVID oral tablets (150 dose pack): Tier 3; QL (40 per 365 days).
    EPCLUSA: Tier 5; PA and SP required; QL (1 per 1 day).
    MAVYRET oral tablet: Tier 2; PA and SP required; QL (3 per 1 day).
    QL — Quantity Limit specified as an amount per time period (e.g., per 1 day, per 28 days, per 365 days).
    Examples of high-cost specialty listings: many oncology and biotech agents (Tier 5) include PA, SP and QL; some have LA or age-based PA restrictions.

    See oncology and biotech entries for common patterns.

    Quantity limits are expressed numerically and tied to a time period (common examples: 1 per 1 day; 3 per 28 days; 30 per 365 days; etc.).

    Numerous QL patterns observed across entries.

    Multiple sclerosis and other specialty neurologic agents are frequently assigned to Tiers 4–5 and include PA; SP; and QL controls, with limits specified per product formulation.
    Rivaroxaban oral tablet: Tier 3; QL (20 per 1 day).
    BIMZELX autoinjector 160 mg/mL: Tier 5; Requirements = PA; QL (1 per 28 days).
    EUCRISA: Tier 4; Requirements = ST (step therapy); QL (1 per 30 days).

    Quantity limit exceptions require prescriber medical necessity statement

    If a prescription exceeds the formulary quantity limit, the prescriber must provide a statement of medical necessity and request a prior authorization for a quantity limit exception.

    • Provide a statement of medical necessity documenting why the standard QL is insufficient.
    • Request the QL exception via the prior authorization process described in the Prior Authorization Process section.
    Step Therapy

    Step therapy: trial documentation and non‑formulary/CED prior authorization

    Step therapy requires documented trials of specified first- and/or second-line medications per AvMed guidelines; non‑formulary or clinically equivalent drug requests must be supported by clinical documentation and submitted through the prior authorization process.

    • Document adequate trials (and therapeutic failures or contraindications) of required step agents in the medical record.
    • For non‑formulary or Clinically Equivalent Drugs (CED), submit clinical documentation establishing medical necessity; CED entries also have prior authorization requirements.
    • Submit requests via the drug authorization request form and include supporting records per the Prior Authorization Process.
    Prior Authorization

    Overview: PA, ST, QL and SP utilization management controls

    Providers should expect utilization management controls across the formulary: certain drugs require prior authorization (PA), some require step therapy (ST), many have quantity limits (QL), and specialty drugs are designated SP with additional handling requirements.

    • Check the Requirements/Limits column for PA, ST, QL, SP, and LA indicators before prescribing.
    • Lack of required PA or ST may result in noncoverage.
    Documentation Required

    Mail‑service dispensing: up to 90‑day supply where allowed by plan

    Mail‑service pharmacy can furnish up to a 90‑day supply of certain medications for members eligible under their group benefits plan; providers may advise patients to use mail service where permitted by benefits.

    • Confirm member group benefits permit mail‑service 90‑day supply prior to prescribing.
    • Advise patients that mail‑service may improve adherence and cost-efficiency when available.
    Prior Authorization

    Examples: prior authorization plus quantity limits (e.g., DIFICID, fidaxomicin)

    Some specific products are subject to both prior authorization and explicit quantity limits (examples in the formulary include DIFICID oral suspension: PA; 100 mL per fill, and fidaxomicin: PA; 20 tabs per fill).

    • When prescribing DIFICID or fidaxomicin confirm PA is obtained and that dispensing does not exceed the per‑fill QL shown on the formulary.
    Prior Authorization

    Specialty drugs: PA, SP, LA and QL commonly required

    Numerous specialty and oncology drugs are designated with PA and SP and often have additional limits such as LA (limited access) and QL; prescribers must follow specialty pharmacy dispensing and authorization requirements for these agents.

    • Confirm whether a specialty pharmacy (SP) is required and submit PA per formulary instructions before dispensing.
    • Be aware of LA flags indicating limited availability at specific pharmacies.
    Note

    Multiple UM flags: verify PA, ST and QL per drug

    The formulary shows many entries with multiple utilization management flags — including PA, ST, and QL — meaning prescribers should verify each drug’s specific requirements before prescribing to avoid coverage delays or denials.

    • Review the Requirements/Limits entry for each drug; do not assume uniform controls across a therapeutic class.
    • Submit required documentation via the PA process when multiple flags are present.
    Prior Authorization

    Age‑based prior authorization requirements

    Some products have age‑based prior authorization requirements (for example, erythromycin ethylsuccinate oral suspension and certain injectable antipsychotics list PA tied to specific age thresholds).

    • Confirm age‑specific PA requirements in the Requirements/Limits column (e.g., PA for Age ≤17 or PA for Age ≥19) and document patient age on PA submissions.
    Note

    Common UM indicators: PA, SP, LA, QL, ST appear across entries

    The formulary uses common utilization modifiers — PA (prior authorization), SP (specialty), LA (limited access), QL (quantity limit), and ST (step therapy) — across many entries; always check the drug line for applicable indicators before prescribing.

    • Interpret the abbreviations using the table legend at the beginning of the formulary.
    • Ensure submitted documentation addresses the specific modifier(s) shown for the requested product.
    Billing Rule

    Quantity limits enforced as amounts per time period (per day/28/365)

    Quantity limits are enforced and specified as counts per time period (examples include limits per day, per 28 days, or per 365 days); prescribers must ensure prescriptions conform to the QL or request an exception via PA.

    • Examples of QL formats: '4 per 1 day', '8 per 28 days', '28 per 365 days', '10 per 30 days'.
    • If a longer or larger supply is needed, submit a QL exception with medical necessity documentation.
    Prior Authorization

    Authorization and limits present on formulary drug lines

    Formulary listings routinely show authorization and limit flags (PA, QL, ST, SP, LA); verify the drug line’s Requirements/Limits before prescribing to determine if prior authorization or other restrictions apply.

    • Drugs marked 'PA' require prior approval before dispensing.
    • Drugs marked 'ST' may require documented trials of specified agents prior to coverage.
    Step Therapy

    Specialty product controls: SP designation and per‑fill QLs

    Certain specialty injectables and opioid antagonists are designated SP and have per‑fill quantity limits (examples include SUBLOCADE and VIVITROL); prescribers must follow specialty dispensing and QL rules for these agents.

    • SUBLOCADE: Requirements / Limits = PA; SP; QL (0.5 per 28 days).
    • VIVITROL: Requirements / Limits = SP (verify PA if indicated for specific products).
    Note

    Formulary requirement codes must be interpreted and followed

    Formulary entries indicate requirement codes (PA, SP, QL, LA, ST) — prescribers must interpret these codes using the table legend and follow the corresponding authorization or dispensing procedures.

    • Refer to the formulary legend at the beginning of the table to interpret symbols and abbreviations.
    • Address the specific requirement code(s) in any PA submission.
    Prior Authorization

    Injectable/long‑acting products: age‑based PA and specified QL frequencies

    Many long‑acting injectable products include prior authorization tied to pediatric age thresholds (Age ≤17) and specify quantity frequencies (e.g., INVEGA SUSTENNA with PA for Age ≤17 and QL per 28 days); include patient age and dosing frequency in PA documentation.

    • Document patient age on PA submissions for products with age‑based PA.
    • Include requested dosing schedule to match QL entries (e.g., QL 0.75 per 28 days).
    Prior Authorization

    Prior authorization and quantity limits noted for multiple drugs (examples)

    Multiple drugs in the formulary list prior authorization and quantity limits — prescribers should check specific drug entries (e.g., TRINTELLIX = PA; QL 1 per 1 day; trifluoperazine = PA for Age ≤17) and submit PA when indicated.

    • TRINTELLIX: PA; QL (1 per 1 day).
    • Trifluoperazine: PA for Age ≤17; QL (4 per 1 day).
    Denial Risk

    Special program / limited‑access products require SP/LA/PA combinations

    Some products are in special program or limited access categories and require combinations of SP, LA and PA (for example, XYWAV and ZURZUVAE show PA; SP; LA); failure to follow restricted access procedures may lead to denial.

    • XYWAV: PA; SP; LA; QL (18 per 1 day).
    • ZURZUVAE: PA; SP; QL (28 per 14 days).
    • Verify dispensing location and specialty pharmacy requirements for LA items.
    Prior Authorization

    Formulary requirement codes summary: act on PA, SP, QL, LA, ST

    The formulary consistently uses requirement codes (PA, SP, QL, LA, ST); prescribers must follow the indicated processes (e.g., obtain PA when marked) to ensure coverage.

    • Always confirm and act on requirement codes present in the drug’s Requirements/Limits field.
    Documentation Required

    Biologic dermatology agents: PA, SP and QL commonly required

    Dermatology biologic entries frequently carry PA, SP, QL and sometimes ST requirements (examples include DUPIXENT and ADBRY); include indication, prior treatments, and dosing in PA submissions for biologics.

    • DUPIXENT PEN 300 mg: PA; SP; QL (4 per 28 days).
    • ADBRY: PA; SP; QL (4 per 28 days).
    Note

    UM indicators in formulary segments: PA, SP, QL, LA frequent

    Utilization management modifiers such as PA, SP, QL and LA appear widely across formulary segments; check the specific drug entry for required authorizations and limits before prescribing high‑cost or specialized products.

    • Many Tier‑5 agents list PA; SP; QL (e.g., EMPAVELI = PA; SP; LA; QL 160 per 28 days).
    • Confirm prior authorization requirements and specialty pharmacy routing as applicable.
    Documentation Required

    Legend reference: interpret PA/QL/ST/SP/LA codes using the table legend

    Refer to the formulary table legend at the beginning of the document to interpret abbreviations and symbols used in Requirements/Limits (PA, QL, ST, SP, LA, ACA, OTC).

    • The legend explains the meaning of PA, QL, ST, SP, LA and other codes used throughout the formulary.
    • If uncertain, contact AvMed Customer Service for clarification.
    Prior Authorization

    Prior authorization and specialty pharmacy requirements for many medications

    Numerous medications in the formulary require prior authorization and specialty pharmacy handling for coverage; confirm PA and SP requirements (and any QL) before prescribing to specialty products.

    • High‑cost specialty drugs listed under Biotechnology frequently require PA; SP and QL (see specific drug rows).
    • Coordinate with the required specialty pharmacy when PA is approved.
    Prior Authorization

    CGM devices: PA and QL on receivers/sensors (document device and need)

    Continuous glucose monitor devices and sensors (e.g., Dexcom G6/G7) are listed with prior authorization, CGM designation and specific quantity limits (e.g., receivers 1 per 365 days, sensors 2–3 per 30 days), so include device type and justification in PA requests.

    • DEXCOM G6 RECEIVER: PA; CGM; QL (1 per 365 days).
    • DEXCOM G6 SENSOR: PA; CGM; QL (3 per 30 days).
    • State device model and clinical need on PA submissions.
    Prior Authorization

    Examples: PA plus QL for selected antidiabetic agents (MOUNJARO, OZEMPIC)

    Selected agents include both prior authorization and specific quantity limits — for example, MOUNJARO requires PA and has QL (2 per 28 days); OZEMPIC oral tablet 1.5 mg requires PA and has QL (30 per 365 days).

    • MOUNJARO: Requirements / Limits = PA; QL (2 per 28 days).
    • OZEMPIC ORAL TABLET 1.5 mg: Requirements / Limits = PA; QL (30 per 365 days).
    Prior Authorization

    Specialty and limited‑access drugs: PA plus SP/LA often required

    Several specialty products are subject to PA plus SP and limited‑access restrictions (e.g., BYLVAY shows PA; SP; LA; QL varying by strength, and CIMZIA shows PA; SP; QL 2 per 28 days); follow the specialty pharmacy and PA instructions to avoid denial.

    • BYLVAY: PA; SP; LA; QL (varies by strength).
    • CIMZIA: PA; SP; QL (2 per 28 days).
    Step Therapy

    Step therapy flags: ST designated products require documented trials

    Some products are explicitly designated as step therapy (ST) on the formulary (for example, PANCREAZE and PERTZYE are listed with ST); document prior required trials or submit a PA for exception.

    • PANCREAZE — Requirements / Limits = ST.
    • PERTZYE — Requirements / Limits = ST.
    • Provide documentation of trials of required agents when requesting coverage for ST‑designated drugs.
    Prior Authorization

    Biotechnology drugs: expect PA, SP and QL requirements

    Many biotechnology drugs require prior authorization, specialty pharmacy designation and quantity limits; prescribers should submit complete clinical documentation and route to the appropriate specialty pharmacy when PA indicates SP.

    • Biotech examples: ARANESP, GRANIX, ACTEMRA, ADALIMUMAB variants — many list PA; SP; QL.
    • Include diagnosis, prior therapy history and dosing rationale in PA submissions for biotech products.
    Documentation Required

    ACA vaccine flags and age‑based PA for some vaccines

    Several vaccine entries are marked 'ACA' indicating Affordable Care Act–related coverage requirements; verify ACA preventive coverage status and any age‑based PA listed on the formulary before ordering.

    • Examples: ABRYSVO lists PA for Age ≤49; COMIRNATY and SHINGRIX are marked ACA.
    • Follow formulary notes for vaccine age or ACA coverage conditions.
    Prior Authorization

    Biotech/rheumatology agents: PA, SP and QLs expected

    Many rheumatology and biotech products are assigned PA, SP and QL; prescribers must include indication, prior treatment, and dosing to support PA requests (examples include ACTEMRA, ADALIMUMAB, ENBREL with PA; SP; QL entries).

    • ACTEMRA ACTPEN — PA; SP; QL (3.6 per 28 days).
    • ADALIMUMAB variants — PA; SP; QL (2 per 28 days).
    Step Therapy

    Step therapy examples: ST designation requires prior trials or PA

    Step therapy examples appear in the formulary (e.g., RASUVO and certain oral products designated ST); prescribers should document trials of required agents or request PA for exceptions.

    • RASUVO (PF) = ST; prescribers must follow step prior requirements or request prior authorization for exception.
    Prior Authorization

    OB/GYN drugs: PA and QL present on select products

    Some OB/GYN products carry prior authorization or quantity limits (for example, CRINONE and DUAVEE require PA; MYFEMBREE requires PA and QL 1 per 1 day; ORIAHNN has PA and QL 2 per 1 day).

    • MYFEMBREE: Requirements / Limits = PA; QL (1 per 1 day).
    • ORIAHNN: Requirements / Limits = PA; QL (2 per 1 day).
    Prior Authorization

    Specialty ophthalmic drugs: PA, SP and specified QL intervals

    Several specialty ophthalmic drugs are subject to prior authorization, specialty pharmacy requirements, and explicit quantity limits expressed per day/28/365 days (examples include CYSTADROPS, OXERVATE and XDEMVY).

    • CYSTADROPS: PA; SP; QL (20 per 28 days).
    • OXERVATE: PA; SP; QL (56 per 720 days).
    • XDEMVY: PA; SP; QL (10 per 365 days).
    Prior Authorization

    Pulmonary/specialty respiratory agents: PA, SP, LA and QL enforcement

    Respiratory and specialty pulmonary agents commonly have utilization controls including PA, SP, LA and QL (for example, ADEMPAS and ALYFTREK entries show PA; SP; QL); ensure PA and any specialty dispensing routes are followed.

    • ALYFTREK: Requirements / Limits = PA; SP; QL (2–3 per 1 day depending on formulation).
    • Confirm PA and specialty pharmacy requirements for pulmonary specialty agents prior to prescribing.
    Prior Authorization

    Tier‑5 specialty drugs: expect PA, SP, LA and QL requirements

    Many Tier‑5 (specialty/high‑cost) drugs list multiple authorization requirements including PA, SP, LA and QL (for example, OPSUMIT lists PA; SP; LA; QL 1 per 1 day); prescribers must follow the coverage pathway indicated on each formulary line.

    • OPSUMIT: Requirements / Limits = PA; SP; LA; QL (1 per 1 day).
    • Verify specialty pharmacy routing and any limited‑access pharmacy constraints before submitting a PA.
    PBM identificationA product may be identified as Generic by AvMed's Pharmacy Benefits Manager.
    Specialty Medication definition — includes 30-day supply limit note
    DefinitionSpecialty Medication — a medication classified by AvMed as a specialty drug, typically for complex or ongoing medical conditions and requiring dispensing by a participating specialty pharmacy.
    Supply limitSpecialty Medications are limited to a 30-day supply via specialty pharmacy.
    Prescribing requirementThese medications must be prescribed by a medical provider; dispensing site may be restricted to participating specialty pharmacies depending on the product.
    Prior Authorization definition
    DefinitionPrior Authorization — the process requiring the ordering prescriber to obtain AvMed approval for certain prescription drugs prior to dispensing per AvMed's guidelines.
    DocumentationThe list of drugs requiring prior authorization is subject to periodic review and modification by AvMed.
    Prescriber responsibilityThe ordering prescriber must obtain approval from AvMed before the drug will be covered for dispensing.
    Step Therapy definition
    DefinitionStep Therapy — a process that requires trial of one or more first- and/or second-line medications specified by AvMed's guidelines before covering an alternative medication.
    ExceptionIf a member cannot use required prior-line medications for medical reasons, the prescriber should request prior authorization with supporting documentation.
    PurposeStep therapy is intended to ensure use of clinically appropriate, generally lower‑cost therapies before alternatives are covered.
    PA abbreviation
    AbbreviationPA — Prior Authorization (approval required before filling certain drugs).
    ContextIf prior authorization is not obtained, the plan may not cover the drug.
    Legend locationAbbreviation meanings are shown at the beginning of the formulary table.
    QL abbreviation
    AbbreviationQL — Quantity Limit (plan limits the amount of the drug it will cover, expressed as a count per time period).
    ExpressionQuantity limits are shown as amounts per time period (e.g., per 1 day, per 28 days, per 365 days).
    ExamplesExamples in the formulary include values like 'QL (2 per 28 days)' or 'QL (30 per 365 days)'.
    SP abbreviation
    AbbreviationSP — Specialty Drug / Specialty Pharmacy designation (indicator that a product is a specialty medication or requires specialty pharmacy handling).
    ImplicationSP items often have additional requirements such as PA, limited dispensing channels, or QL constraints.
    DispositionMany Tier 5 products are marked SP in the formulary listings.
    ST abbreviation
    AbbreviationST — Step Therapy (requires trial of specified drugs first before covering another).
    ProcessWhen ST applies, coverage of the requested drug may be contingent on documented trials of required medications or an approved prior authorization exception.
    AppearanceST appears in the formulary Requirements / Limits column where step therapy is required for coverage.
    Formulary tiers — mapping (1–5, 9) with meanings
    Tier 1Preferred Generic — lower-cost preferred generic products.
    Tier 2Generic — generic products.
    Tier 3Preferred Brand — preferred brand-name products.
    Tier 4Non‑Preferred Brand — non-preferred brand-name products.
    Tier 5Specialty Drugs — specialty/high-cost medications, often with PA/SP/QL requirements.
    Tier 9Zero Cost Share Preventive Drugs — ACA preventive or administration‑coded items with zero cost‑share when applicable.
    Drug Tier — numerical tier assignments (1-5)
    Tier 1Preferred Generic (numerical tier assignment 1).
    Tier 2Generic (numerical tier assignment 2).
    Tier 3Preferred Brand (numerical tier assignment 3).
    Tier 4Non‑Preferred Brand (numerical tier assignment 4).
    Tier 5Specialty Drugs (numerical tier assignment 5).
    Abbreviations indicating requirements/limits (PA, QL, SP, LA, ST)
    PAPA = Prior Authorization (requires approval before dispensing).
    QLQL = Quantity Limit (specified maximum amount per time period).
    SPSP = Specialty (specialty drug designation / specialty pharmacy requirement).
    LALA = Limited Availability / Limited Access (may be available only at certain pharmacies).
    STST = Step Therapy (trial of specified medications required before coverage).
    Utilization control abbreviations (PA, SP, QL, LA)
    PAPA — Prior Authorization required for certain drugs listed in the formulary.
    SPSP — Specialty requirement or designation applied to many high‑cost agents.
    QLQL — Quantity limits specified for many products (numerical per time period).
    LALA — Limited Availability (may be restricted to certain dispensing locations).
    Utilization control abbreviations (PA, SP, LA, QL, ST) — legend usage
    Legend usagePA = prior authorization; SP = specialty pharmacy / specialty designation; LA = limited availability; QL = quantity limit; ST = step therapy — full legend is at the beginning of the table.
    Interpretation noteThe Requirements / Limits column uses these abbreviations to indicate utilization controls for each drug.
    ReferenceSee the beginning of the formulary table for the complete symbols and abbreviation legend.
    Quantity limits (QL) — expressed as count per time period
    FormatQuantity limits (QL) are expressed as a count per a time period (e.g., '1 per 1 day', '3 per 28 days', '30 per 365 days').
    PurposeQLs limit the covered amount per prescription or time period for one copay or coinsurance, based on FDA labeling and guidelines.
    Examples from formularyExamples include QL (2 per 28 days), QL (224 per 28 days), QL (30 per 365 days).
    Table symbols/abbreviations — refer to table legend at start
    Legend locationTable symbols and abbreviations (e.g., PA, QL, ST, SP, LA) are defined at the beginning of the formulary table.
    GuidanceReview the table legend at the start of the formulary to interpret the Requirements / Limits column.
    Cross-referenceEach drug line indicates '1 = Drug Tier' and '2 = Requirements / Limits' referencing the legend.
    prior authorization (PA) shorthand
    ShorthandPA — used as the shorthand notation for prior authorization in the Requirements / Limits column.
    UsageAppears next to drug entries to indicate that prior authorization is required before the drug will be covered.
    Legend locationMeaning defined at the beginning of the formulary table.
    quantity limit (QL) shorthand
    ShorthandQL — used as shorthand for Quantity Limit, indicating a numeric cap per specified time period.
    ExamplesShown as QL (3 per 30 days), QL (1 per 365 days), etc., adjacent to drug entries.
    InterpretationSee table legend for exact formatting and units per entry.
    step therapy (ST) shorthand
    ShorthandST — used as shorthand for Step Therapy in the formulary Requirements / Limits column.
    ImplicationIndicates that a trial of specified medication(s) is required before coverage of another agent.
    ExceptionsPrescribers may request a prior authorization exception when step therapy cannot be met for medical reasons.
    specialty pharmacy (SP) shorthand
    ShorthandSP — shorthand indicating Specialty Drug designation or requirement for Specialty Pharmacy dispensing.
    ConsequenceSP items commonly have PA and QL entries and may be limited to participating specialty pharmacies.
    Tier correlationMost SP‑designated products appear in Tier 5 (Specialty Drugs).
    limit/age or life-cycle assertion (LA) shorthand
    ShorthandLA — shorthand for Limited Availability / Limited Access, indicating restricted dispensing availability (may be available only at certain pharmacies).
    ActionCall Customer Service or refer to formulary notes for pharmacy availability details when LA is indicated.
    ContextLA often appears with PA and SP on high‑cost or limited‑distribution products.
    Formulary requirement abbreviations — repeated legend references
    Legend repeatFormulary requirement abbreviations (PA, QL, SP, ST, LA) are repeated throughout the table and their meanings are given at the table start.
    Use in tableEach drug entry lists tier (1) and Requirements / Limits (2) referencing these abbreviations.
    Additional flagsOther flags (e.g., ACA, OTC) also appear and are defined in the legend.
    Requirement codes — PA, SP, QL, LA, ST
    Codes listRequirement codes used: PA = prior authorization; SP = specialty drug designation; QL = quantity limit; LA = limited access; ST = step therapy.
    ApplicationThese codes appear in the Requirements / Limits column and determine coverage conditions for listed drugs.
    ExamplesMany Tier 5 biologics list combinations like 'PA; SP; QL' or 'PA; SP; LA; QL'.
    Formulary modifiers — PA, SP, QL, LA (legend reference)
    Formulary modifiersPA = prior authorization; SP = specialty pharmacy; QL = quantity limit; LA = limited availability — full legend at the beginning of the formulary table.
    InterpretationModifiers explain utilization management requirements applied to each drug entry.
    LocationRefer to table start for complete definitions and any plan‑specific notes.
    CGM designation used in requirements/limits
    CGM designationCGM — Continuous Glucose Monitor designation used in Requirements / Limits for devices and sensors (e.g., 'PA; CGM; QL (1 per 365 days)').
    ExamplesDEXCOM G6 RECEIVER: PA; CGM; QL (1 per 365 days); DEXCOM G6 SENSOR: PA; CGM; QL (3 per 30 days).
    ImplicationCGM items are managed with PA and QL specific to device/sensor frequency.
    Prior Authorization (PA) shorthand — duplicate reference
    Shorthand repeatPA — shorthand for prior authorization used consistently across the formulary Requirements / Limits column.
    Definition sourceDefined in the Definitions section at the start of the formulary document.
    Practical notePA entries often require submission of clinical documentation per AvMed's Prior Authorization Process.
    Specialty Pharmacy (SP) shorthand — duplicate reference
    Shorthand repeatSP — shorthand for Specialty Drug / Specialty Pharmacy designation, used repeatedly in Requirements / Limits.
    Associated controlsSP commonly appears together with PA and QL for Tier 5 medications.
    Defined whereMeaning included in the list of abbreviations at the beginning of the formulary.
    Quantity Limit (QL) shorthand — duplicate reference
    Shorthand repeatQL — shorthand for Quantity Limit used consistently in the Requirements / Limits column.
    FormatDisplayed as 'QL (number per time period)'.
    Defined whereSee the abbreviations legend at the start of the table for meaning and examples.
    Formulary requirement abbreviations — extended list including ACA/OTC
    Extended listFormulary requirement abbreviations include PA (Prior Authorization), SP (Special program / Specialty), QL (Quantity Limit), LA (Limited Access), ST (Step Therapy), ACA (Affordable Care Act preventive coverage), OTC (Over‑the‑counter designation).
    Legend usageThese abbreviations are used as flags in the Requirements / Limits column and are defined at the beginning of the table.
    ExamplesACA flags appear on preventive vaccines and certain contraceptives; OTC appears where applicable.
    formulary requirement flags — PA, SP, QL, ACA, ST
    Requirement flagsFormulary flags commonly used: PA, SP, QL, ACA, ST — indicating prior authorization, specialty designation, quantity limits, ACA preventive coverage, and step therapy respectively.
    Where seenThese flags appear across biotechnology, vaccine, and other therapeutic listings in the formulary.
    ActionRefer to the legend and product line for exact requirements when a flag is present.
    tier — tier numbers indicate placement on 5-tier formulary
    Tier meaningTier numbers indicate placement on the 5-tier formulary (1–5); certain items use Tier 9 for zero cost‑share preventive drugs.
    UsageTier assignment affects member cost‑sharing and coverage conditions.
    ReferenceFull tier mapping is provided in the list of abbreviations at the start of the formulary (1–5, 9).
    Formulary requirement abbreviations — PA, SP, QL, ST, ACA
    Common abbreviationsFormulary requirement abbreviations used repeatedly include PA, SP, QL, ST, ACA — their meanings are defined in the table legend.
    Practical noteWhen present, these abbreviations determine additional coverage steps or limits for a given drug.
    Where definedSee the beginning of the formulary table for complete definitions and any plan‑specific notes.
    Formulary abbreviations (PA, SP, QL, LA, ST) — general note on legend presence
    Legend presenceThe formulary table uses symbols and abbreviations (PA, SP, QL, LA, ST) whose meanings are defined at the beginning of the full table; users should consult that legend for interpretation.
    Document noteMultiple cross‑references in the document direct readers to the table start for symbol definitions.
    ApplicationInterpret Requirements / Limits values on each drug line using the legend definitions.